MK-8690

Merck Sharp & Dohme LLC · Phase 2 active Small molecule

At a glance

Generic name	MK-8690
Also known as	PRA052
Sponsor	Merck Sharp & Dohme LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MK-8690 CI brief — competitive landscape report
MK-8690 updates RSS · CI watch RSS
Merck Sharp & Dohme LLC portfolio CI